Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Morita M, Tamiya M, Fujimoto D, Tamiya A, Suzuki H, Hirano K, Fukuda Y, Yokoyama T, Kominami R, Kanazu M, Uchida J, Hara S, Yamashita S, Tomioka H.
Morita M, et al. Among authors: yamashita s.
BMC Cancer. 2020 Feb 3;20(1):93. doi: 10.1186/s12885-020-6582-4.
BMC Cancer. 2020.
PMID: 32013910
Free PMC article.